Myocarditis associated with infliximab: A case report and review of the literature

Inflammatory Bowel Diseases

Volumn 17, Issue 7, 2011, Pages 1633-1634

  Slattery, Eoin ^a   Ismail, Nuriah ^a   Sheridan, Juliette ^a   Eustace, Karen ^a   Harewood, Gavin ^a   Patchett, Stephen ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCORTISONE; INFLIXIMAB; MESALAZINE;

ADULT; CARDIOTOXICITY; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG SAFETY; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; MALE; MYOCARDITIS; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79958823139     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21546     Document Type: Letter

References (8)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
2. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811. (Pubitemid 40824691)
3. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107: 3133-3140. (Pubitemid 36793081)
4. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Ann Intern Med. 2003; 138: 807-811.
5. Fenoglio JJ, McAllister HA, Mullick FG,. Drug related myocarditis. I. Hypersensitvity myocarditis. Hum Pathol. 1981; 12: 900-907.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245. (Pubitemid 12149145)
7. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007; 116: 2216-2233. (Pubitemid 350060359)
8. Wenzl HH, Reinisch W, Jahnel J, et al. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol. 2004; 16: 767-773. (Pubitemid 39062568)